Oppenheimer Sticks to Its Sell Rating for Intuitive Surgical (ISRG)

Oppenheimer analyst Suraj Kalia maintained a Sell rating on Intuitive Surgical (ISRGResearch Report) today and set a price target of $365.00. The company’s shares closed last Wednesday at $810.06, close to its 52-week high of $826.81.

According to TipRanks.com, Kalia is a 4-star analyst with an average return of 9.2% and a 57.1% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Inspire Medical Systems, and Cardiovascular Systems.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Intuitive Surgical with a $696.25 average price target.

See today’s analyst top recommended stocks >>

Based on Intuitive Surgical’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.08 billion and net profit of $314 million. In comparison, last year the company earned revenue of $1.13 billion and had a net profit of $397 million.

Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ISRG in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.